March 27, 2012 by staff
Cholesterol Shot, A monthly injection of an experimental drug made by the U.S. biotech firm Amgen reduced patients’ cholesterol by up to 66 percent, according to a small study described at a U.S. cardiology conference.
The early phase 1 clinical trial, designed mainly to see if the treatment was safe, followed 51 patients who received a shot of the drug, AMG 145, either once every two or every four weeks.
Among trial subjects were already taking high doses of cholesterol-lowering drugs, known as statins, and who got the shot every two weeks, the dangerous type of cholesterol in their bodies dropped by an average of 63 percent by the eighth week.
And those who were on low doses of statins and received the drug every four weeks saw a slightly higher average drop in LDL cholesterol — 66 percent by the end of the same time period.
No deaths or adverse events were recorded during the preliminary study, which was presented for the the first time on Sunday at the American College of Cardiology annual conference.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.